Bioremediation still not living up to hopes

Slow acceptance of biotreatment systems, perhaps due to limited regulatory pressures, has prompted Celgene Corp. to de-emphasize that line of business and increase its efforts on its chiral chemical business and

Read the full 319 word article

How to gain access

Continue reading with a
two-week free trial.